- Phase 4 study shows INGREZZA (valbenazine) significantly improves quality of life in older adults with tardive dyskinesia.
- Study involves 29 patients aged 65+, using validated assessment tools EQ-5D-5L and Sheehan Disability Scale.
- Findings align with previous studies, reinforcing long-term safety and efficacy in this high-risk demographic.
Neurocrine Biosciences (NBIX, Financial) has unveiled new Phase 4 data demonstrating significant patient-reported improvements in health-related quality of life and functional status among older adults aged 65 years and above who continued treatment with INGREZZA (valbenazine) capsules. The findings were shared at the 2025 American Association of Nurse Practitioners (AANP) National Conference in San Diego.
The study involved a post-hoc analysis of 29 participants, revealing that those who maintained their regimen of INGREZZA experienced marked enhancements in their functional status compared to those switched to a placebo. This analysis applied two clinically validated tools: the EQ-5D-5L for assessing health status in five dimensions, and the Sheehan Disability Scale for evaluating functional impairment.
INGREZZA's efficacy in improving life quality measures highlights its potential as a crucial treatment for older adults, who are particularly vulnerable to the physical, functional, and social impacts of tardive dyskinesia. This newly presented data builds upon previous KINECT 3 and KINECT 4 studies, which also supported the drug's long-term safety and effectiveness in this demographic.
